Extemporaneous Preparations in the Pharmacotherapy of Nervous System Disorders: Pharmaceutical Management, Marketing, Analysis, Application
Keywords:management, marketing, technology, analysis, application, extemporaneous preparation, sedative action
Pharmaceutical management, marketing, pharmaceutical analysis, clinical and pharmacological properties for the use of an extemporaneous drug in the pharmacotherapy of nervous system disorders were studied. The previous experience of the author in the development of new combined drugs of various clinical and pharmacological groups was used. The composition of an extemporaneous drug with sedative pharmacological properties (sodium bromide, novocaine, tincture of valerian) is proposed. The manufacturing technology in pharmacy conditions, qualitative and quantitative indicators of active substances, as well as storage conditions and shelf life of the new extemporaneous drug were developed. The search, development, manufacture in a pharmacy and the use of extemporaneous drugs will contribute to the improvement of planning, organization, and control of the processes of medical and pharmaceutical assistance to patients in conditions of armed conflict. Coordination of medical, pharmaceutical, human, financial, natural, technological, and social resources is necessary to meet the challenges of today.
Shapovalov V. Suicide among young people in Ukraine and Estonia: interdisciplinary study of the problem in the system of legal relations "doctor-patient-pharmacist-lawyer". SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.3. P.1-16. URL: https://doi.org/10.53933/sspmpm.v3i3.106. DOI: https://doi.org/10.53933/sspmpm.v3i3.106
Shapovalova V. Pharmacotherapy of Depressive disorders in conditions of coronavirus disease: pharmacoeconomic experimental study. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.3. P.1-11. URL: https://doi.org/10.53933/sspmpm.v3i3.101. DOI: https://doi.org/10.53933/sspmpm.v3i3.101
Shapovalova V. Forensic and pharmaceutical risks in the organization of pharmacotherapy of covid, post-covid and long-covid disorders. COVID-19 and vaccination practice standards. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 4. P. 1–24. URL: https://doi.org/10.53933/sspmpm.v2i4.69. DOI: https://doi.org/10.53933/sspmpm.v2i4.69
Gudzenko A.A., Shapovalov V.V. (Jr.), Shapovalova V.А. et al. Organizational and legal, forensic and pharmaceutical researches of pharmaceutical provision for mental disorders of victims in the emergencies at regional level. Likars’ka Sprava. 2018. Vol. 7-8. P. 149-157. URL: https://doi.org/10.31640/JVD.7-8.2018(24). DOI: https://doi.org/10.31640/JVD.7-8.2018(24)
Hayduchok I. Pharmacotherapy of systemic vasculitis combined with cryoglobulinemic syndrome using pharmacoeconomic approaches. Global Journal of Health Science. 2021. Vol.13. No.7. P.78-88. DOI: 10.5539/gjhs.v13n7p78. URL: https://doi.org/10.5539/gjhs.v13n7p78. DOI: https://doi.org/10.5539/gjhs.v13n7p78
Shapovalova V.O., Shekera O.G., Shapovalov V.V. et al. Control regime of drugs for pharmacotherapy of depression in combatants. An information letter about innovations Ukrmedpatentinform of the Ministry of Health of Ukraine. Kyiv: Ukrmedpatentinform of the Ministry of Health of Ukraine; 2018: 282 – 2018. 8 p.
Suicide. WHO. 17.06.2021. URL: https://www.who.int/news-room/fact-sheets/detail/suicide.
Development challenges for medicines for central nervous system disorders. European Medical Agency. 29.11.2016. URL: https://www.ema.europa.eu/en/news/development-challenges-medicines-central-nervous-system-disorders.
Gomez-Mancilla B., Marrer E., Kehren J. et al. Central nervous system drug development: An integrative biomarker approach toward individualized medicine. Neurotherapeutics. 2005. No.2. DOI: https://doi.org/10.1602/neurorx.2.4.683. DOI: https://doi.org/10.1602/neurorx.2.4.683
Shapovalova V.O., Vasina Yu.V., Shapovalov V.V. etc. Regime of control of analgesic extemporaneous medicinal K. Ukrmedpatentinform of the Ministry of Health of Ukraine, 2017. No. 151–2017, issue 1. – 5 p.
Vasina Yu.V. Organizational and legal study of the composition and control regime of an extemporaneous medicinal product for otolaryngology with the aim of preventing forensic pharmaceutical risks. Pharmacist. 2016. No. 3, supplement. P. 7–18.
Vasina Yu.V., Shapovalov V.V., Shapovalova V.O. etc. Pharmaceutical law: extemporaneous prescription in the pharmacotherapy of intestinal colic in children under one year. Ukrainian Herald of Psychoneurology. 2015. Vol. 23, issue 3 (84), appendix. P. 58–62.
Vasina Yu.V. Pharmaceutical law: search for new effective methods of treatment of atopic dermatitis in children (on the example of extemporaneous formulation). Ukrainian Herald of Psychoneurology. 2015. Vol. 23, issue 3 (84), appendix. P. 85–90.
Vasina Yu.V., Shapovalov V.V., Shapovalova V.O. Pharmaceutical law: study of the level of accessibility of patients suffering from diabetes to the circulation of extemporaneous medicinal products. Ukrainian Herald of Psychoneurology. 2014. Vol. 22, issue 2, appendix. P. 21–25.
Vasina Yu.V., Shapovalova V.O., Shapovalov V.V. Pharmaceutical law: study of the state of circulation of extemporaneous medicinal products at the regional level. Pharmacist. 2014. No. 4. P. 78–84.
Shapovalova V.A., Shapovalov V.V. The clinical efficacy of the combined drug agent Valcophen in children. Likars'ka sprava. 1999. No.1. P.124–126. URL: https://pubmed.ncbi.nlm.nih.gov/10424023/.
Shapovalova V.O., Mykhailov V.S., Shapovalov V.V. The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative – in experiments on mice. Fiziolohichnyi zhurnal. 1999. Vol.45. No.3. P.114–117. URL: https://pubmed.ncbi.nlm.nih.gov/10439301/.
Vasina Yu.V. Pharmaceutical law: definition of the regime of control of extemporaneous formulation, which includes potent substances. Pharmaceutical journal. 2013. No. 2. P. 37–43. URL: http://www.irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?I21DBN=LINK&P21DBN=UJRN&Z21ID=&S21REF=10&S21CNR=20&S21STN=1&S21FMT=ASP_meta&C21COM=S&2_S21P03=FILA=&2_S21STR=pharmazh_2013_2_7.
Vasina Yu.V. Standardization and organization of the production of medicinal products: subject-quantitative accounting of extemporaneous medicinal products of various classification and legal groups in health care institutions. Ukrainian Herald of Psychoneurology. 2013. Vol. 21, issue 2 (75), appendix. P. 18–21.
Vasina Yu.V., Shapovalov V.V., Shapovalova V.O. etc. Forensic pharmaceutical study of the control regime of chloramphenicol (chloramphenicol) as part of extemporaneous dosage forms. Management, economics and quality assurance in pharmacy. No. 1(21). 2012. S.74-78. URL: http://188.8.131.52/cgi-bin/Webirbis3/cgiirbis_64.exe?LNG=&Z21ID=&I21DBN=ZK&P21DBN=ZK&S21STN=1&S21REF=10&S21FMT=fullwebr&C21COM=S&S21CNR=30&S21P01=0&S21P02=1&S21P03=A=&S21STR=%D0%9D%D0%B0%D0%B7%D0%B0%D1%80%D0%BE%D0%B2%D0%B0,%20%D0%9E.%20%D0%A1.
Shapovalova V.O., Zbrozhek S.I., Shapovalov V.V. et al. Content analysis of pharmacy establishments of Ukraine, where extemporaneous medicinal products are manufactured. Public health. 2017. Vol. 6. No. 3–4. P. 77–83. DOI: 10.22141/2306-24184.108.40.2067.123498. URL: https://health-society.zaslavsky.com.ua/index.php/journal/article/view/119. DOI: https://doi.org/10.22141/2306-24220.127.116.117.123498
Shapovalov V.V., Zbrozhek S.I., Shapovalova V.O. et al. Organizational and legal regulation procedure for circulation of extemporal medicines based on pharmaceutical law. Annals of Mechnikov Institute. 2017. No. 4. P.33-37. DOI: 10.5281/zenodo.1133771. URL: http://www.imiamn.org.ua/journal/4_2017/zmist4_2017.html
Morofuji Y., Nakagawa S. Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr. Pharm. Des. 2020. Vol.26. N.13. Р.1466-1485. URL: https://pubmed.ncbi.nlm.nih.gov/32091330/ DOI: https://doi.org/10.2174/1381612826666200224112534
Danon J.J., Reekie T.A., Kassiou M. Challenges and opportunities in central nervous system drug discovery. Trends in Chemistry. 2019. Vol. 1, Issue 6. P. 612-624. DOI: https://doi.org/10.1016/j.trechm.2019.04.009. DOI: https://doi.org/10.1016/j.trechm.2019.04.009
Shapovalova V.O., Vasina Yu.V., Shapovalov V.V. et al. Study of the circulation system of extemporaneous medicinal products in Ukraine on the basis of pharmaceutical law. Pharmaceutical journal. 2016. No. 1. P. 77-85. URL: http://www.irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?I21DBN=LINK&P21DBN=UJRN&Z21ID=&S21REF=10&S21CNR=20&S21STN=1&S21FMT=ASP_meta&C21COM=S&2_S21P03=FILA=&2_S21STR=pharmazh_2016_1_15.
Shapovalova V.O., Shapovalov V.V., Stefanov O.V. et al. Clinical use of medicines. Medicines in neurology, psychiatry and narcology. Kharkiv: "Fact". 2003. P. 228–438.
Ching-Liang Hsieh, Lixing Lao, Yi-Wen Lin, et al. Complementary and alternative medicine for the treatment of central nervous system disorders. Hindawi. 2014. Vol. 2014. Article ID175152. URL: https://www.hindawi.com/journals/ecam/2014/175152/. DOI: https://doi.org/10.1155/2014/175152
Shapovalova V.O., Zabolotny V.A., Depeshko I.T. etc. Pharmaceutical analysis of medicines. Kharkiv, "Rubikon". 1995. 400 p.
Shapovalova V.O., Stefanov O.V., Trachtenberg I.M. etc. Clinical use of over-the-counter drugs. Pharmaceutical law in safe self-medication: drugs dispensed without a doctor's prescription. Kharkiv: Fakt. 2005. P. 30–634.
Shapovalova V., Shapovalov V., Vasina Ju. et al. Legislation in pharmacy, forensic pharmacy and evidence-based pharmacy: Study book. 3rd ed. Kharkiv, 2011. 160 p.
Shapovalova V. The ICD-11 for the Twenty-First Century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol.2. No.1. P.1-13. URL: https://doi.org/10.53933/sspmpm.v2i1.3. DOI: https://doi.org/10.53933/sspmpm.v2i1.37
How to Cite
Copyright (c) 2023 Viktoriia Shapovalova
This work is licensed under a Creative Commons Attribution 4.0 International License.